Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Peritonitis frequency 	1964	2310	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38), or in the most frequent serious SSIs of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Overall adverse events frequency 	1785	1907	Adverse events were more frequent in the HA/CMC powder group versus the no adhesion barrier group (63% vs. 39%; P <0.001),
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Overall adverse events frequency 	19224	19389	The overall frequency of adverse events was significantly higher in the HA/CMC powder versus the no adhesion barrier group (66/105 [63%] vs. 41/104 [39%]; P <0.001).
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Overall surgical site infections	1964	2155	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38),
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Serious surgical site infections	1964	2310	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38), or in the most frequent serious SSIs of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Serious surgical site infections	1964	2155	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38),
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Anastomotic fistula frequency 	1964	2310	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38), or in the most frequent serious SSIs of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Overall surgical site infections	1964	2310	There were no statistically significant differences between the HA/CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs. 9%; P = 0.38), or in the most frequent serious SSIs of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).
Hyaluronic acid/carboxymethylcellulose	No adhesion barrier	Serious adverse events frequency 	1785	1963	Adverse events were more frequent in the HA/CMC powder group versus the no adhesion barrier group (63% vs. 39%; P <0.001), as were serious adverse events (28% vs. 11%; P <0.001).
